Gilead Sciences, Inc.  

(Public, NASDAQ:GILD)   Watch this stock  
Find more results for GILD
+0.57 (0.82%)
Feb 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 69.05 - 70.07
52 week 65.38 - 103.10
Open 69.32
Vol / Avg. 7.38M/12.22M
Mkt cap 92.90B
P/E 7.04
Div/yield 0.52/2.97
EPS 9.94
Shares 1.32B
Beta 1.11
Inst. own 77%
Jan 31, 2017
Q4 2016 Gilead Sciences Inc Earnings Release (Estimated)
Jan 9, 2017
Gilead Sciences Inc at JPMorgan Healthcare Conference
Nov 29, 2016
Gilead Sciences Inc at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 42.34% 44.38%
Operating margin 55.26% 58.02%
EBITD margin - 58.02%
Return on average assets 21.89% 24.82%
Return on average equity 68.81% 71.25%
Employees 8,000 -
CDP Score - -


United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.

Officers and directors

John C. Martin Ph.D. Executive Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
John F. Milligan Ph.D. Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Robin L. Washington Chief Financial Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Kevin B. Young CBE Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
Norbert W. Bischofberger Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 60
Bio & Compensation  - Reuters
Kathleen Watson Executive Vice President - Human Resources
Bio & Compensation  - Reuters
Gregg H. Alton Executive Vice President - Corporate and Medical Affairs
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
James R. Meyers Executive Vice President - Worldwide Commercial Operations
Age: 50
Bio & Compensation  - Reuters
Martin Silverstein M.D. Executive Vice President - Strategy
Age: 48
Bio & Compensation  - Reuters
John F. Cogan Jr. Ph.D. Lead Independent Director
Age: 68
Bio & Compensation  - Reuters